^
Association details:
| Biomarker: | SORT1 expression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | sudocetaxel zendusortide (TH 1902) (Tubulin polymerization promoter, Microtubule stabilizer, Sortilin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TH1902 in Patients With Advanced Solid Tumors
Excerpt:
...Histologically or cytologically confirmed TNBC, HR+ breast cancer, epithelial ovarian cancer, endometrial cancer, cutaneous melanoma, thyroid cancer, SCLC, prostate cancer or other cancer known to express SORT1 that is refractory or resistant to standard therapy (replaces inclusion criterion #3)....
Trial ID:
Source:
Title:
The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells
Published date:
09/09/2022
Excerpt:
Immunophenotyping of hTNBCSC and hOvCSC was performed by flow cytometry and confirmed the expression of SORT1...In vivo, using immunosuppressed nude mice xenografts, TH1902 significantly inhibited the growth of hTNBCSC and hOvCSC xenografts (~80% vs. ~35% for docetaxel) when administered weekly as intravenous bolus for three cycles at 15 mg/kg, a dose equivalent to the maximal tolerated dose of docetaxel.
DOI:
10.3390/pharmaceutics14091910
Source:
Title:
1313 - TH1902, a docetaxel peptide-drug conjugate, shows pre-clinical efficacy in several Sortilin-positive (SORT1+) cancers
Published date:
03/10/2021
Excerpt:
Pre-clinical in vivo studies were performed in human SORT1+ tumor xenografts grown in mice including TNBC (MDA-MB-231 and HCC-70), melanoma (SK-MEL-28), colorectal (HT-29) and pancreatic (PANC-1) cancer models. Mice were treated with either TH1902 or docetaxel by IV bolus injections...In all cases, TH1902 showed more potent inhibition than Docetaxel.
